Skip to main content
OpenTrials
Completed

NCT Number: NCT00592332

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

Alprazolam (Xanax) will blunt the body's ability to defend itself from low blood sugar.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vanderbilt University

Nashville, Tennessee, 37232, United States

About this study

Due to the fundamental importance of glucose as a cerebral fuel, a complex and redundant counterregulatory response to hypoglycemia exists in man. Some studies have shown that prior activation of GABA(A) receptors may result in blunting of counterregulatory responses during next day hypoglycemia.

The Specific Aim is to determine if repeated activation of GABA(A) receptors using Alprazolam will result in blunting of neuroendocrine, ANS and metabolic counterregulatory mechanisms during next day hypoglycemia in T1DM and healthy man.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 16 (8 males, 8 females) Type 1 diabetes patients aged 18-45 yr.
  • 16 (8 males, 8 females) healthy controls aged 18-45 yr.
  • HbA1c > 7.0% (Type 1 diabetes patients)
  • Had diabetes for 2-15 years (Type 1 diabetes patients)
  • No clinical evidence of diabetic tissue complications (Type 1 diabetes patients)
  • Body mass index 21-30 kg · m-2
  • Normal bedside autonomic function
  • Normal results of routine blood test to screen for hepatic, renal, and hematological abnormalities
  • Female volunteers of childbearing potential: negative HCG pregnancy test

Exclusion criteria

  • Prior history of poor health: any current or prior disease condition that alters carbohydrate metabolism and prior cardiac events and/or evidence for cardiac disease
  • Hemoglobin of less than 12 g/dl
  • Abnormal results following screening tests
  • Pregnancy
  • Subjects unable to give voluntary informed consent
  • Subjects with known liver or kidney disease
  • Subjects taking steroids
  • Subjects taking beta blockers
  • Subjects on anticoagulant drugs, anemic, or with known bleeding diseases

Treatment and study plan

alprazolam

Drug

1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)

Other names: Xanax

Control Group

Other

control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.

Primary outcomes

  1. Catecholamine levels

    Time frame: Comparative study performed every 6-8 weeks

Sponsors and collaborators

Lead sponsor

Vanderbilt University

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 2

Important dates

Study start
2005
Primary completion
2007
Study completion
2009
First posted
Jan 14, 2008
Registry last updated
Dec 11, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.